Navigation Links
Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
Date:1/3/2012

noclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on the Regeneron web site at www.regeneron.com.

Regeneron Forward-Looking StatementThis news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of EYLEA and Regeneron's product candidates and research and clinical programs now underway or planned, the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize EYLEA and other products and drug candidates, competing drugs that may be superior to EYLEA and Regeneron's products and drug candidates, uncertainty of market acceptance of EYLEA and Regeneron's products and drug candidates, the possibility of EYLEA sales meeting or exceeding any of the cumulative U.S. sales targets triggering payments to Genentech described in this news release, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property and pending or future litigation relating th
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
2. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
3. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
4. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
5. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
6. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
7. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
8. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
9. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
10. Regeneron Reports Second Quarter 2011 Financial and Operating Results
11. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 An experimental drug ... as a viable first treatment for anemia of inflammation, according ... the treatment published online today in Blood ... (ASH).    Anemia is a condition that ... do not function properly. When an individual has anemia, the ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com ... report is available in its catalogue: ... Application and Approval of Imported Medical ... (2014 Edition) ... Now, Chinese regulations on medical devices ...
(Date:8/27/2014)... BOSTON , Aug. 27, 2014  Columbia Laboratories, ... Company"), a provider of pharmaceutical development, clinical trial manufacturing, ... industry, today announced that it will participate at the ... Investment Conference, to be held in New ... conference at 11:15am on September 9, 2014 at the ...
Breaking Medicine Technology:Drug Represents First Potential Treatment for Common Anemia 2Drug Represents First Potential Treatment for Common Anemia 3Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 2Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 3Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 4Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 5Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 6Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 7Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 8Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 9Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 10
... Reinforces Anti-Inflammatory Properties of Red Hot ,Super,Fruit, ... study shows tart cherries,one of today,s hottest "Super ... of type 2 diabetes and cardiovascular disease,in animals. ... researchers,today at the Experimental Biology annual meeting. As ...
... 2008 Data from five studies sponsored,by Ortho ... National Kidney,Foundation (NKF) 2008 Spring Clinical Meetings from ... PROCRIT(R) (Epoetin alfa)., The data include studies ... (EPO) and darbepoetin alfa (DARB), evaluate medical costs,related ...
Cached Medicine Technology:Tart Cherries May Reduce Inflammation, Lower Risk for Type 2 Diabetes & Heart Disease 2Tart Cherries May Reduce Inflammation, Lower Risk for Type 2 Diabetes & Heart Disease 3Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 2Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 3Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 4Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 5Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 6
(Date:8/28/2014)... Bellevue, WA (PRWEB) August 28, 2014 ... a free downloadable ebook guide to the ... prepare themselves for surgery, the procedure itself, and how ... helpful tips and candid explanations. Dr. McIntosh also discusses ... how to help ensure that the procedure is as ...
(Date:8/28/2014)... San Diego, CA (PRWEB) August 28, 2014 ... age of 40 and are considered the leading cause of ... of the eye’s natural lens behind the iris, cataracts are ... year 2020, mostly due to an aging population. Cataracts are ... eye. Each year, Dr. Michael Tracy of Carlsbad Eye ...
(Date:8/28/2014)... NJ (PRWEB) August 28, 2014 Registration ... Run For The Warriors® in Holmdel, New Jersey on ... take place at the New Jersey Vietnam Veterans’ Memorial ... at the PNC Bank Arts Center. All proceeds of ... national nonprofit dedicated to restoring a sense of self, ...
(Date:8/28/2014)... York (PRWEB) August 28, 2014 An unprecedented ... and neck issues, Cloud 9 Spine offers their resources online ... problems can quickly become a brick wall of discouragement as ... a professional opinion, Cloud 9 Spine offers a ... technology merged with human interaction that sets Cloud 9 Spine ...
(Date:8/28/2014)... August 28, 2014 Alpine, NJ resident ... of his team, Zebras In Tiaras, to benefit the ... be held October 26, 2014 in Foley Square, New ... immunodeficiency community. Primary immunodeficiency diseases (PI) are a group ... which part of the body’s immune system is missing ...
Breaking Medicine News(10 mins):Health News:The Ultimate Guide to the Tummy Tuck Surgery eBook is Released by Dr. Bryan McIntosh 2Health News:Cataract Awareness Month an Opportunity to Focus on Vision Care and Ocular Health 2Health News:Hope For The Warriors Announces Second Annual NJ Run 2Health News:Making Waves on the East Coast, Cloud 9 Spine is Helping Patients Find Appointments With Local Spine Doctors 2
... financial results -, LAVAL, QC, Oct. 29 /PRNewswire-FirstCall/ ... it will host a conference call on,Friday, November 7 ... 2008,financial results. Labopharm will report its third quarter 2008 ... same day., To access the conference call by ...
... and KING OF PRUSSIA, Pa., Oct. 29 HighPoint,Solutions ... that as part of its growth strategy, it has ... new office. The new location will,be at 8750 W. ... office is conveniently located near O,Hare International,Airport., Glenn ...
... In Vitro Fertilization and ... Intrauterine Insemination Procedures, LA JOLLA, Calif., Oct. 29 ... it has entered into a,series of agreements to acquire exclusive ... to the use of,adenosine 5,-triphosphate (ATP) to improve motility of ...
... Sato Sports Plaza to investigate new muscle,training methods, ... to expand,global health and fitness research and partnerships, ... an international science and health,exchange to highlight scientific ... with Sato Sports Plaza of,Japan is the first ...
... PRGO ; TASE) today announced that it ... Drug Administration for its Abbreviated New,Drug Application (ANDA) ... mg. The national brand,s,exclusivity ends prior to the ... will be marketed under store brand labels and ...
... ARLINGTON, Va., Oct. 29 For Veterans Day,the ... a new 14-page,brochure on posttraumatic stress disorder (PTSD), ... line at http://www.nami.org/PTSD and is intended ... illness, along,with their families and caregivers., "PTSD ...
Cached Medicine News:Health News:Labopharm to host conference call Friday, November 7, 2008 at 8:30 a.m. (ET) 2Health News:HighPoint Solutions Expands with New Chicago Office 2Health News:Duska Therapeutics Acquires Technology for ATPotent Sperm Motility Program 2Health News:Duska Therapeutics Acquires Technology for ATPotent Sperm Motility Program 3Health News:New Program Internationalizes Health and Fitness Research 2Health News:Perrigo Announces FDA Tentative Approval for Ibuprofen PM 2Health News:Veterans Day: New PTSD Brochure - 'Transmission of Trauma' Can Span Generations 2
... The ACONO H. pylori Rapid Test Strip ... the qualitative detection of antibodies to Helicobacter ... or plasma to aid in the diagnosis ... years of age and older. They are ...
Clearview H. pylori II uses rapid, two-step technology for the direct detection of H. pylori antibodies. , ,The patented, innovative technology used by Clearview H. pylori II provides highly sen...
... read, qualitative immunochromatographic method for rapid detection ... that grows in the stomach and is ... gastric cancers. FlexSure HP, available for use ... provides the physician with the opportunity to ...
... The Acceava Mononucleosis test provides superior ... with a simple procedure that provides ... evaluations with competitive products will convince ... attributes enable you to deliver improved ...
Medicine Products: